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Abstract
Background: Transforming Growth Factor β (TGF-β) plays an important role in tumor invasion and metastasis. We set 
out to investigate the possible clinical utility of TGF-β antagonists in a human metastatic basal-like breast cancer 
model. We examined the effects of two types of the TGF-β pathway antagonists (1D11, a mouse monoclonal pan-TGF-
β neutralizing antibody and LY2109761, a chemical inhibitor of TGF-β type I and II receptor kinases) on sublines of basal 
cell-like MDA-MB-231 human breast carcinoma cells that preferentially metastasize to lungs (4175TR, 4173) or bones 
(SCP2TR, SCP25TR, 2860TR, 3847TR).
Results: Both 1D11 and LY2109761 effectively blocked TGF-β-induced phosphorylation of receptor-associated Smads 
in all MDA-MB-231 subclones in vitro. Moreover, both antagonists inhibited TGF-β stimulated in vitro migration and 
invasiveness of MDA-MB-231 subclones, indicating that these processes are partly driven by TGF-β. In addition, both 
antagonists significantly reduced the metastatic burden to either lungs or bones in vivo, seemingly independently of 
intrinsic differences between the individual tumor cell clones. Besides inhibiting metastasis in a tumor cell autonomous 
manner, the TGF-β antagonists inhibited angiogenesis associated with lung metastases and osteoclast number and 
activity associated with lytic bone metastases. In aggregate, these studies support the notion that TGF-β plays an 
important role in both bone-and lung metastases of basal-like breast cancer, and that inhibiting TGF-β signaling results 
in a therapeutic effect independently of the tissue-tropism of the metastatic cells. Targeting the TGF-β pathway holds 
promise as a novel therapeutic approach for metastatic basal-like breast cancer.
Conclusions: In aggregate, these studies support the notion that TGF-β plays an important role in both bone-and lung 
metastases of basal-like breast cancer, and that inhibiting TGF-β signaling results in a therapeutic effect independently 
of the tissue-tropism of the metastatic cells. Targeting the TGF-β pathway holds promise as a novel therapeutic 
approach for metastatic basal-like breast cancer.
Background
In the normal mammary gland, Transforming Growth
Factor-β (TGF-β) controls tissue homeostasis by inhibit-
ing cell cycle progression, inducing differentiation and
apoptosis, and maintaining genomic integrity [1-3]. In
addition, TGF-β orchestrates the response to tissue injury
and mediates repair by inducing epithelial-to-mesenchy-
mal transition (EMT) and cell migration in a time-and
space-limited manner [4,5]. Following extracellular acti-
vation of TGF-β, the ligand binds to the type II TGF-β
receptor (TβR-II), which then recruits and activates the
type I receptor (TβR-I/Alk-5)[6]. In general, the activated
TβR-I/Alk-5 phosphorylates receptor-associated Smad2
and Smad3, which form complexes with Smad4. These
activated Smad complexes accumulate in the nucleus
where, along with co-activators and cell-specific DNA-
binding factors, they regulate gene expression and ulti-
mately cell growth and tissue repair [7,8]. More recently it
has become apparent that TGF-β also activates the recep-
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tor-associated Smads1 and -5 in a TβR-I/ALK5-ALK2/3-
dependent manner, and that this arm of the signaling
pathway may be the predominant one driving EMT and
cell migration [9-11].
Several correlative studies have suggested that the
TGF-β signaling pathway plays a critical role in progres-
sion of human breast cancer. For example, there appears
to be direct correlation between tumor burden and
plasma TGF-β levels in patients with breast cancer [12-
15]. In addition, breast cancer tissue appears to express
higher levels of TGF-β than normal breast tissue [16-19].
Furthermore, a significantly greater fraction of invasive
carcinomas express immunodetectable TGF-β than in
situ carcinomas [19,20].
Besides these correlative studies, genetic manipulation
of the intrinsic TGF-β signaling pathway in mammary
cancer cells has provided direct evidence for its impor-
tance in driving the metastatic process (Reviewed in
[21]). Thus, McEarchern et al. [22] reported that express-
ing a dominant negative truncated TGF-β type II recep-
tor (TGFBR2) gene in highly metastatic 4T1 murine
mammary carcinoma cells significantly restricted their
ability to establish distant metastases. Along the same
lines, Yin et al. [23] showed that expression of a domi-
nant-negative  TGFBR2  receptor mutant in the human
MDA-MB-231breast cancer cell line inhibited the extent
of experimental bone metastases. Moreover, reversal of
the dominant-negative signaling blockade by overex-
pressing a constitutively active TβR-I receptor in these
breast cancer cells increased production of parathyroid
hormone-related protein (PTHrP) by the tumor cells and
enhanced their osteolytic bone metastases. In similar
studies, Tang et al. showed that introducing a dominant-
negative TGFBR2 gene into highly metastatic MCF10Ca1
mammary carcinoma cells resulted in a reduction in
experimental pulmonary metastases [24]. More recently,
using genetic depletion experiments, several groups have
demonstrated that Smad4 [25-27] as well as Smad2 and -
3 [28] contribute to the formation of osteolytic bone
metastases by MDA-MB-231 cells. Similarly, interference
with Smad2/3 signaling strongly suppressed experimental
lung metastases of aggressive MCF10Ca breast carci-
noma cells [29]. In aggregate, these studies indicate that,
even though human breast carcinoma cells are typically
refractory to TGF-β-mediated growth suppression, the
remaining intrinsic TGF-β signaling contributes to the
formation of macrometastases in several different sec-
ondary sites, including bone and lungs [23-25]. These
studies have generated considerable enthusiasm for
exploiting the TGF-β pathway as a novel therapeutic tar-
get (reviewed in [21,30]). However, a number of key ques-
t i o n s  w i l l  n e e d  t o  b e  a n s w e r e d  b e f o r e  e m b a r k i n g  o n
clinical trials of TGF-β pathway antagonists in breast can-
cer.
First, it is necessary to validate the results of genetic
depletion experiments using treatment with pharmaco-
logical inhibitors of TGF-β signaling. Currently, two main
strategies for targeting TGF-β signaling are in early stages
of clinical development [21,31-33]: The first involves
trapping of TGF-β ligands with soluble TβR-II exorecep-
tor molecules [34] or with isoform-selective antibodies.
These include lerdelimumab (selective for TGF-β2) and
metelimumab (selective for TGF-β1) ,  a s  w e l l  a s  t h e
murine 1D11or humanized GC-1008 (Fresolimumab)
antibodies that neutralize all three major TGF-β isoforms
[33]. The second approach involves chemical inhibition
of the TGF-β receptor kinases [33]. There are a number
of key pharmacological and pharmacodynamic differ-
ences between these two classes of TGF-β antagonists:
First, ligand traps are selective for particular ligand(s). For
example, 1D11 neutralizes all 3 major active TGF-β iso-
forms (TGF-β1, -2, and -3)[35], but does not bind other
ligands in the TGF-β superfamily, such as activins and
BMPs. In contrast, most of the chemical kinase inhibitors
inhibit not only Alk-5, -but also the Alk-4 and -7 kinases,
thus blocking both TGF-β and activin signaling [36-39].
In addition, some of these chemicals, such as LY2109761
(Eli Lilly & Co.), target both the TβR-I and -II kinases
[40]. Moreover, the neutralizing antibodies selectively
inhibit biologically active TGF-βs, while the receptor
kinase inhibitors also shut off the basal Smad phosphory-
lation that is seen in the absence of exogenously added
TGF-β, so called "endogenous" signalling [41]. Finally, tis-
sue and cell penetration of antibodies is often less effi-
cient than of small chemicals, and the target protein
needs to be accessible to the antibody to be effectively
neutralized. On the other hand, chemicals have more
favorable pharmacological properties than the neutraliz-
ing antibodies. Because of these differences in target
specificity and pharmacological properties, it is difficult
to predict which of these compounds will have superior
anti-metastatic properties in vivo.
The second major question that needs to be addressed
is whether or not metastases to different organ sites are
equally dependent on TGF-β signaling. In the MDA-MB-
231 model system, over-expression of a small number of
genes is sufficient to selectively confer either bone-tropic
or lung-tropic metastatic properties [42,43]. However,
the gene expression signature associated with bone
m e t a s t a s e s  i s  d i s t i n c t l y  d i f f e r e n t  f r o m  t h a t  a s s o c i a t e d
with lung metastases, indicating that a very different type
of adaptation is required for MDA-MB-231 to effectively
colonize bone marrow or a pulmonary microenviron-
ment [42]. On the other hand, several of the bone- (IL-11,
CTGF and CXCR4) and lung metastasis genes (GRO1/
CXCL1, MMP-2, ID1, PTGSG2/COX2) are regulated by
TGF-β [41]. Therefore, we hypothesize that cell autono-
mous TGF-β signaling plays an important role in pulmo-Ganapathy et al. Molecular Cancer 2010, 9:122
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nary metastases as well as in bone metastases. However,
not all bone metastases may be equally dependent on
autocrine TGF-β signaling. Besides rapidly growing bone
metastases, some animals developed detectable skeletal
metastases following a prolonged period (six months
after inoculation) of dormancy (Lu et al. In Preparation)
[44]. Cell lines derived from such "post-dormancy"
metastases (MDA-231-2860TR and MDA-231-3847TR)
retained clear bone-tropism when re-injected into ani-
mals, but they lacked expression of previously identified
TGF-β-driven bone metastasis genes, such as CXCR4 or
IL-11 [44]. Thus, primary lytic bone metastases may be
more dependent on TGF-β signaling than the ones that
develop following dormancy.
In our studies, we used 1D11, a mouse monoclonal
pan-TGF-β neutralizing antibody [35] and LY2109761, a
chemical inhibitor of both TβR-I and TβR-II receptor
kinases [40] to determine whether or not these two
antagonists have non-overlapping spectra of anti-meta-
static activity against breast cancer and whether anti-
metastatic activity of TGF-β pathway inhibitors varies
based on tissue tropism using a human basal cell-like
breast cancer model.
Results
Several investigators have demonstrated that genetic
inactivation of the TGF-β signaling pathway reduces the
ability of human basal-like breast cancer cells to metasta-
size to bones or lungs [23-27,29]. The first question we
addressed is whether treatment with pharmacological
TGF-β antagonists can reproduce the effects of geneti-
cally inactivating the tumor cell autonomous TGF-β sig-
naling pathway in vitro and  in vivo.  T o  t h i s  e n d ,  w e
utilized two types of TGF-β pathway antagonists, i.e.
1D11, a mouse monoclonal pan-TGF-β neutralizing anti-
body and LY2109761, a chemical inhibitor of TGF-β type
I and II receptor kinases. We employed experimental
metastasis assays in which MDA-MB-231 human breast
carcinoma cells were injected either into the left cardiac
ventricle to generate osteolytic bone metastases, or into
the tailvein to produce pulmonary metastases. To deter-
mine whether the efficacy of the TGF-β antagonists
depended on the type of metastases, we used two types of
highly bone-tropic (SCP2-TR and SCP25-TR) or lung-
tropic (4175-TR and 4173) subclones of MDA-MB-231
that had been isolated by in vivo selection [25,43,45]. In
addition, during this in vivo selection process, some ani-
mals had developed detectable skeletal metastases only
after a prolonged period (six months after inoculation) of
dormancy [44]. Clonal sublines derived from such "post-
dormancy" metastases, 2860TR and 3847TR, retained
clear bone-tropism when re-inoculated by intracardiac
injection. Because their gene expression profiles were
quite distinct from the SCP lines, this allowed us to
address to what extent the efficacy of TGF-β antagonists
was dependent on intrinsic properties of tumor cell
clones derived from the same parental line.
Distinct morphology of MDA-MB-231 derived subclones in 
three-dimensional (3D) culture
Morphologically, the six MDA-MB-231 subclones were
indistinguishable from each other when cultured on a
plastic substratum. However, when we examined the
growth patterns of the various MDA-MB-231 subclones
in 3D Matrigel®  cultures, significant differences were
noted (Figure 1). Parental MDA-MB-231 cells have previ-
ously been reported to display a stellate growth pattern in
3D culture [46]. As shown in Figure 1, the two lung-tropic
MDA-MB-231 subclones, 4175-TR and 4173, largely
retained this distinct stellate morphology, which was
associated with pronounced invasion into the surround-
ing Matrigel®. In contrast, the two bone-tropic subclones,
SCP2TR and SCP25TR, displayed a mass-like phenotype,
while colonies formed by the two post-dormant sub-
clones, 2860TR and 3847TR, displayed a looser, so-called
Figure 1 Morphology of MDA-MB-231-derived subclones in 3D 
organotypic culture. Cells were plated onto a layer of growth factor-
reduced Matrigel® matrix as described in Materials and Methods. Con-
focal microscopy images of 9 day-old 3D cultures labeled with Alexa-
488-phalloidin were obtained. Colonies of early (SCP2TR and SCP25TR) 
and post-dormant (2860TR and 3847TR) bone-tropic subclones dis-
played a mass-like and grape-like morphology, respectively [46]. In 
contrast, the two lung-tropic subclones (4175TR and 4173) exhibited a 
stellate invasive phenotype [46].Ganapathy et al. Molecular Cancer 2010, 9:122
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grape-like, phenotype (Figure 1)[46]. Thus, each of the
three clonal subsets displayed a distinct growth pattern in
this 3D culture environment, presumably reflecting
intrinsic differences in gene expression profiles and their
unique metastatic properties in vivo [25,43-45].
Effects of TGF-β antagonists on Smad activation in MDA-
MB-231 cell clones in vitro
Since activation of receptor associated Smads (R-Smads)
is a required step in TGF-β signaling, we examined the
effects of treatment with TGF-β antagonists on TGF-β-
induced Smad phosphorylation. As shown in Figure 2A,
TGF-β treatment induced phosphorylation of Smad2 and
-3 in each of the six cell lines. In addition, TGF-β clearly
induced phosphorylation of Smad-1 and -5 in the highly
metastatic SCP2TR, 4175TR and 4173 clones, to a much
lesser extent in the two post dormancy clones (2860TR
and 3847TR), and not at all in the moderately metastatic
SCP25TR cells (Figure 2A). These findings suggest that
the degree of Smad1 and -5 activation may reflect the
intrinsic metastatic ability and/or tissue tropism of the
different MDA-MB-231 subclones.
Pretreatment of cells with either the TβR-I and TβR-II
dual kinase inhibitor, LY2109761, or the pan-TGF-β neu-
tralizing murine antibody, 1D11, effectively inhibited
TGF-β-induced activation of all R-Smads. Given the dif-
Figure 2 Effects of TGF-β antagonists on Smad activation in MDA-MB-231-derived metastatic subclones. A. Cells were starved in serum free 
DMEM medium overnight and incubated with vehicle or TGF-β antagonist for 15 minutes. Subsequently, TGF-β (100 pM) was added, and cells were 
incubated for an additional hour. The levels of phosphorylated Smad-2,-3 and -1/5/8 were determined by Western blotting. Induction of Smad-2 and 
-3 phosphorylation by exogenous TGF-β was effectively inhibited by either LY2109761 (2 μM) or 1D11 (10 μg/ml) in all six subclones. TGF-β induced 
Smad1 and -5 phosphorylation most strongly in the most metastatic bone-tropic (SCP2TR) and lung-tropic (4175TR and 4173) subclones, and to a 
lesser extent in the 2860TR and 3847TR cells. Activation of these BMP Smads was also inhibited by both antagonists. B. To assess the ability of TGF-β 
antagonists to induce dephosphorylation of R-Smads, bone-tropic SCP2TR cells were treated with TGF-β for 1.5 h, followed by treatment with the 
antagonists for the indicated time-periods. The receptor kinase inhibitor, LY2109761, induced dephosphorylation of activated Smad-2 and -3 more 
rapidly than the pan- TGF-β neutralizing antibody, 1D11.Ganapathy et al. Molecular Cancer 2010, 9:122
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ferent pharmacological properties of the two compounds,
we also examined their effects on Smad signal termina-
tion. Treatment of SCP2TR cells with LY2109761
induced dephosphorylation of Smad2 and -3 much more
rapidly (t1/2= 45 minutes) than 1D11 (t1/2 = 2 h)(Figure
2B). Thus, while both LY2109761 and 1D11 were equally
capable of blocking TGF-β-induced signal activation, the
kinetics with which they terminated TGF-β signaling
were quite distinct.
Effects of TGF-β antagonists on cell proliferation migration 
and invasion of MDA-MB-231 clones in vitro
Treatment with exogenous TGF-β failed to significantly
affect the growth of MDA-231-4175TR, -4173, -
SCP25TR, -2860TR and -3847TR cells in vitro (Figure
3A). Moreover, even though TGF-β inhibited SCP2TR
cell growth by 30% and this reached statistical signifi-
cance (p = 0.029), this was far less than in non-neoplastic
cells [39]. Most importantly, neither of the two TGF-β
pathway antagonists significantly stimulated growth of
any of the six MDA-MB-231 clones (Figure 3A). Previous
studies have suggested that basal cell-like breast cancer
invasion and migration might be driven by TGF-β [47].
Hence, we determined the effects of each of the antago-
nists on tumor cell motility and invasion in vitro. As
shown in Figures 3B and 3C, the MDA-MB-231 sub-
clones differed markedly in terms of intrinsic motility and
invasiveness, with SCP2TR and 4175TR being the most
motile and invasive. Moreover, exogenous TGF-β most
strongly stimulated in vitro migration and invasion of
these two MDA-MB-231 clones. Interestingly, neither
antagonist seemed to have a significant effect on the basal
migration rates of any of the subclones (Figure 3B, C).
However, treatment with either LY2109761 or 1D11
effectively counteracted TGF-β-induced migration as
well as invasion of SCP2TR and 4175TR cells in vitro.
Finally, neither antagonist affected the intrinsic invasion
rates of these cell lines in Transwell® assays, with the
exception of 4173 cells (Figure 3C). Consistent with these
findings, treatment of lung-tropic MDA-MB-231 4173
cells in 3-dimensional Matrigel® cultures with LY2109761
inhibited spontaneous invasion and caused the cells to
revert to a mass-like growth pattern in a dose-dependent
manner (Figure 3D). These findings suggested that the
invasive properties of MDA-MB-231 4173 colonies in 3D
cultures are dependent on autocrine TGF-β signaling.
Because SCP2TR and 4175TR cells displayed the high-
est basal migration and invasion rates, were most strongly
stimulated by TGF-β, and were most susceptible to both
TGF-β pathway antagonists, these two MDA-MB-231
subclones were selected for in vivo studies.
Effects of TGF-β antagonists on bone metastases in vivo
Several studies have demonstrated that tumor cell auton-
omous genetic inactivation of the TGF-β signaling path-
way by knock-down of TGFBR2 or SMAD4 reduced the
ability of MDA-MB-231 human basal-like breast cancer
cells to metastasize to bone [23,25-27]. Whether these
effects could be reproduced by treatment with TGF-β
antagonists was determined in experimental metastasis
assays in which we inoculated athymic nude mice with
bone-tropic SCP2TR cells via intracardiac injection. In
separate experiments, mice were treated with 5 mg/kg
1D11 given intraperitoneally (i.p.) three times per week
or with 50 mg/kg LY2109761 twice daily by gavage,
beginning 1-3 days following tumor cell inoculation. No
drug-associated toxicities were observed and animals
maintained their body weight during the entire course of
treatment (data not shown). Because the tumor cell lines
expressed a luciferase reporter construct, metastases
could be monitored in vivo using bioluminescence imag-
ing (BLI) (Figure 4A). Treatment with 1D11 antibody
reduced the burden of bone metastases by approximately
70-80% (p = 0.001) compared to treatment with either
vehicle or isotype control antibody (Figure 4A). Similarly,
LY2109761 treatment inhibited bone metastases com-
pared to vehicle controls by approximately 55% (p =
0.039) (Figure 4A). Results obtained by BLI were con-
firmed post mortem using Faxitron analysis (Figure 4B).
Perhaps most importantly, treatment with the 1D11 anti-
body as a single agent was associated with a trend
towards prolongation of survival of the test animals (Fig-
ure 4C).
Effects of TGF-β antagonists on pulmonary metastases in 
vivo
To address the question whether TGF-β signaling plays a
similar role in pulmonary metastases as in bone metasta-
ses, mice were inoculated with lung-tropic 4175TR cells
via tail vein injection (Figure 4D). In separate experi-
ments, mice were then treated either with 5 mg/kg 1D11
given intraperitoneally (i.p.) three times per week or with
50 mg/kg LY2109761 twice daily by gavage, beginning 1-3
days following tumor cell inoculation. Treatment with
1D11 antibody reduced the metastatic burden to lungs by
approximately 25-40% (p = 0.001) compared to treatment
with either vehicle or isotype control antibody (Figure
4D). Similarly, LY2109761 treatment reduced the burden
of lung metastases compared to vehicle by approximately
40% (p = 0.079) (Figure 4C). These results indicate that
the establishment of pulmonary metastases is also, at
least in part, dependent on TGF-β signaling. As was the
case with bone metastases, the fact that both neutraliza-
tion of TGF-β itself and selective chemical inhibition of
the type I and -II TGF-β receptor kinases had similar
effects in inhibiting pulmonary metastases is indicative of
a specific role for TGF-βs (as opposed to activins or
BMPs) in this process.Ganapathy et al. Molecular Cancer 2010, 9:122
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Effect of 1D11 on primary versus post-dormant bone 
metastases in vivo
MDA-MB-231 bone tropic subclones derived from "post-
dormancy" bone metastases (2860 TR and 3847 TR) have
a distinct gene expression that does not include the previ-
ously identified bone metastasis gene signature (Lu et al.
In Preparation)[44]. These differences between "primary"
and "post dormant" bone-tropic MDA-MB-231 clones
allowed us to address to what extent the efficacy of TGF-
β antagonists might differ as a function of intrinsic prop-
erties of tumor cell clones derived from the same parental
line. Mice were inoculated with post dormant bone tropic
2860 TR cells via intracardiac injection. Treatment with
1D11 antibody reduced the metastatic burden to bones
by between 55-80% (p = 0.019) compared to treatment
with vehicle or isotype control antibody (Figure 4E).
Thus, TGF-β neutralizing antibody 1D11 inhibited bone
metastases from 2860 TR cells to a similar degree as
those from SCP2TR cells (Figure 4A). In aggregate, the
anti-metastatic activity of TGF-β targeted agents appears
to be relatively independent of the intrinsic differences in
gene expression signatures of individual subclones.
Molecular target inhibition by TGF-β antagonists in vivo
To substantiate the inhibition of TGF-β signaling by 1D11
or LY2109761 treatment in vivo, we ascertained the levels
of phospho-Smad2 in uninvilved lung tissue and mRNA
of several TGF-β target genes in kidney tissue of treated
animals. Phospho-Smad2 levels were reduced compared
to vehicle controls in protein extracts from lungs of ani-
Figure 3 Effects of TGF-β and TGF-β antagonists on cell growth and cell-motility and -invasion of MDA-MB-231 subclones. A. Cells were plat-
ed at 2 × 104/well in 24-well plates and incubated in the presence of vehicle (Blue bars), TGF-β (100 pM) (Green bars), 1D11 (10 μg/ml) or LY2109761 
(2 μM) (Red bars) or a combination of TGF-β and an inhibitor (Yellow bars) for 72 h and cell numbers determined. Treatment with exogenous TGF-β 
failed to significantly inhibit growth of any of the subclones, with the exception of SCP2TR cells. Neither 1D11 nor LY2109761 stimulated tumor cell 
growth of any of the MDA-MB-231 subclones. Means ± SD of at least three independent experiments. Unpaired 2-sided t-test ± Welch correction was 
used to compare treatment with or without TGF-β antagonist. For cell-motility (B) and -invasion (C) assays, MDA-MB-231 sublines were cultured in 
uncoated and Matrigel®-coated PET inserts, respectively. Cells were treated with TGF-β (100 pM) and either LY2109761 (2 μM) or 1D11 (10 μg/ml) for 
24 h. MDA-MB-231 subclones SCP2TR and 4175TR displayed the greatest motility and invasion, which were further stimulated by exogenous TGF-β. 
Moreover, both TGF-β pathway antagonists significantly inhibited TGF-β-induced motility and invasion in these two cell lines. Means ± SD of at least 
three independent experiments. Unpaired 2-sided t-test ± Welch correction was used to compare treatment with TGF-β alone with TGF-β plus inhib-
itor. D. Lung-tropic 4173 cells were plated onto a layer of growth factor-reduced Matrigel® matrix, followed by treatment with either vehicle or varying 
concentrations of LY2109761 for 9 days. Phase contrast microscopy images of 9 day-old 3D cultures labeled with Alexa-488-phalloidin were obtained. 
Numbers refer to the four representative colonies from each culture shown. As can be seen, treatment with LY2109761 inhibited invasion into sur-
rounding Matrigel® in a dose-dependent manner, resulting in a reversal from a stellate to mass-like phenotype.
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mals treated with either LY2106791 or 1D11 (Figure 5A).
As shown in Figure 5B, LY2109761 treatment signifi-
cantly lowered basal CTGF and PAI-1mRNA expression
l e v e l s ,  c o n s i s t e n t  w i t h  b l o c k a d e  o f  e n d o g e n o u s  T G F - β
signaling in vivo. In contrast, basal TGF-β target genes
transcript levels were not affected by 1D11 treatment
(Figure 5C), suggesting that this agent may selectively
spare endogenous TGF-β signaling [41].
Mechanisms of action of TGF-β antagonists in vivo
In order to assess possible mechanisms of action of the
two TGF-β antagonists on metastases in vivo, we com-
pared the rates of tumor cell proliferation and apoptosis
between metastases in the different treatment groups.
Consistent with our in vitro results, neither antagonist
had a significant effect on tumor cell proliferation (Ki67
staining, Figure 6A) or apoptosis (TUNEL staining, Fig-
ure 6B). In contrast, treatment with either 1D11 or
LY2109761 resulted in a significant reduction in microve-
ssel density in lung metastases as determined by CD34
staining (Figure 6C). This suggested that these com-
pounds act, at least in part, by inhibiting tumor angiogen-
esis. These findings were entirely consistent with our
previous findings using a murine model of metastatic
Figure 4 Effects of TGF-β antagonists on experimental MDA-MB-231 human breast cancer cell metastases in vivo. A. Mice were inoculated 
with bone-tropic SCP2TR cells via intracardiac injection and treated with vehicle, 13C4 isotype control antibody or 1D11 anti-TGF-β antibody (Left 
panel) or with vehicle or LY2109761 (Right panel). Bone metastases were monitored by BLI once weekly. Median values per group are shown. Treat-
ment with 1D11 antibody reduced the burden of bone metastases by approximately 70-80% (p = 0.001) compared to treatment with either vehicle 
or isotype control antibody. Similarly, LY2109761 treatment inhibited bone metastases compared to vehicle controls by approximately 55% (p = 
0.039). B. Faxitron analysis of fore-and hind limbs of tumor-bearing animals. Both 1D11 and LY2109761 treatment resulted in significant reductions in 
the total extent of SCP2TR-induced osteolytic bone lesions. Unpaired 2-sided t-test was used for comparisons. C. Treatment of bone-tropic SCP2TR 
inoculated mice with the 1D11 antibody was associated with prolongation of survival of the test animals (n = 10) compared to control animals (n = 
12) (p = 0.06, Log-Rank test). D. Mice were inoculated with lung-tropic 4175TR cells via tailvein injection and treated with vehicle, 13C4 or 1D11 (Left 
panel) or with vehicle or LY2109761 (Right panel). Treatment with 1D11 antibody reduced the metastatic burden to lungs by approximately 25-40% 
(p = 0.001, Kruskall-Wallis test) compared to treatment with either vehicle or isotype control antibody. Similarly, LY2109761 treatment reduced the 
burden of lung metastases compared to vehicle by approximately 40% (p = 0.079). E. Treatment of mice inoculated with post dormancy bone tropic 
2860TR cells with 1D11 antibody reduced the metastatic burden to bones by between 55-80% compared to treatment with vehicle or isotype control 
antibody (p = 0.019).
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mammary cancer treated with a different selective TGF-β
type I receptor kinase inhibitor [48]. As shown in Figure
4, both 1D11 and LY2109761 treatment resulted in signif-
icant reductions in osteolytic bone lesions. Consistent
with this, histological staining for tartrate resistant acid
phosphatase (TRAP) activity, a marker of active osteo-
clasts, showed that treatment with 1D11 significantly
reduced the number of TRAP-positive osteoclasts
located at the tumor:bone interface (Figure 6D). In sum-
mary, in our xenograft mouse models, the anti-metastatic
properties of TGF-β signaling antagonists appear to be
mediated both by tumor cell autonomous effects and by
modulating tumor:host interactions via several different
mechanisms, including inhibition of angiogenesis in the
case of lung metastases and inhibition of osteoclast activ-
ity in the case of bone metastases.
Discussion
Our study clearly demonstrates that treatment with TGF-
β antagonists inhibits the ability of bone-as well as lung-
tropic MDA-MB-231 cell lines to establish experimental
metastases in vivo. This convincingly demonstrates that
TGF-β signaling plays an important role in this process,
largely independently of the organo-tropism of the tumor
Figure 5 Pharmacodynamic effects of TGF-β antagonists in vivo. A. Protein extracts from snap-frozen uninvolved lung tissue of mice treated with 
vehicle and LY2109761 and of mice treated with controls and 1D11 were prepared and subject to Western blotting using rabbit phosphoSmad2 an-
tibody (1:1000 dilution). Whole cell lysate from SCP2TR was used as a control (Co). Treatment with both antagonists resulted in a reduction of phos-
phorylated Smad2 levels. Values represent the means and SD of three mice per group. Unpaired 2-sided t-test was used for comparisons. B. RNA was 
extracted from snap-frozen uninvolved kidneys of mice treated with vehicle or LY2109761 using Trizol reagent (Invitrogen) and purified using RNeasy 
mini columns (Qiagen) according to the manufacturer's instructions. Transcript levels of CTGF and PAI-1 were assayed using the QuantiTect™ Probe 
RT-PCR Kit on a Mx4000® Multiplex Quantitative PCR System (Stratagene). Treatment with LY2109761 significantly reduced mRNA levels of both CTGF 
and PAI-1 relative to GAPDH mRNA. Values represent the means and SD of three mice per group. Unpaired 2-sided t-test was used for comparisons. 
C. RNA was extracted from snap-frozen lungs of mice treated with vehicle, isotype control antibody or 1D11 and transcript levels determined as de-
scribed above. No significant reduction in CTGF or PAI-1 mRNA levels could be detected in the 1D11-treated group. Values represent the means and 
SD of two independent experiments, 3 mice per group. Unpaired 2-sided t-test was used for comparisons.
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cells (Figure 4). Our results are consistent with several
previous studies that have reported anti-metastatic activ-
ity of individual TGF-β antagonists in in vivo models of
human mammary cancer. For example, Arteaga et al. [49]
reported that intraperitoneal injections of the murine
TGF-β neutralizing antibody, 2G7 (Genentech®), was able
to suppress lung metastases of MDA-MB-231 breast can-
cer cells that had been inoculated intraperitoneally. More
recently, using the same experimental metastasis assay we
employed, Ehata et al. [50] reported that treatment with a
TGF-β type I receptor kinase inhibitor, Ki26894,
decreased bone metastases and prolonged survival of
mice inoculated with highly bone-tropic human MDA-
MB-231-D breast cancer cells. Similarly, Korpal et al. [27]
recently reported that treatment with LY2106791 inhib-
ited early skeletal metastases.
In our hands, both classes of TGF-β antagonist signifi-
cantly reduced the burden of skeletal and pulmonary
metastases (Figure 4). Prior to our study, little informa-
tion was available to determine whether the anti-meta-
static efficacy of TGF-β antagonists on human breast
carcinoma was organ site-specific. Separate reports indi-
cated that the anti-TGF-β antibody 1D11 appeared to
inhibit skeletal-or pulmonary metastases of the murine
Figure 6 Mechanism of action of TGF-β antagonists in vivo. Lung metastases from mice treated with LY2109761 and 1D11 were stained for mark-
ers of cell proliferation (Ki-67), apoptosis (TUNEL), and microvascular endothelial cells (CD34). At least 600 nuclei were counted in 5 randomly selected 
high-power (400 ×) fields in areas of viable tumor to determine the proportion of Ki-67-or TUNEL-positive cells. The total number of CD34+ microve-
ssels were counted in 5 randomly selected high-power (400 ×) fields in areas of viable tumor. A. Neither antagonist affected tumor cell proliferation 
(Ki-67; p = 0.49 for the LY2109761 group and p = 0.12 for the 1D11 group) or B. apoptosis (TUNEL assay; p = 0.12 for the LY2109761 group and p = 
0.06 for the 1D11 group). C. However, microvessel density was significantly reduced in tumors of mice treated with LY2109761 and 1D11 compared 
with their respective controls (p = 0.018 for the LY2109761 group and p = 0.024 for the 1D11 group). D. Histological staining for tartrate resistant acid 
phosphatase (TRAP) activity (red color) of bone metastases from representative vehicle-(left images) and 1D11-treated (right images) mice. The num-
bers of TRAP positive cells per mm2 of tumor adjacent to bone in bone metastases from 1D11-treated mice (n = 9 lesions) relative to vehicle-treated 
mice (n = 17 lesions) are shown. Treatment with 1D11 was associated with a significant reduction in the number of TRAP-positive osteoclasts (p = 
0020). Unpaired 2-sided t-test (± Welch correction) was used for comparisons.
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4T1 mammary carcinoma cells. Thus, treatment with
1D11 resulted in a significant reduction in the number of
4T1 lytic bone lesions [51]. Using the same 4T1 cell line,
Nam et al. showed that treatment with 1D11 significantly
suppressed both the number and size of tumor metasta-
ses to the lungs [52-54]. Although one has to be cautious
about direct comparisons across studies, the therapeutic
effects of TGF-β neutralizing antibodies against 4T1-
derived skeletal or pulmonary metastases appeared to be
of a similar order of magnitude.
Although our results are consistent with previous
reports of anti-metastatic activity of individual TGF-β
antagonists in in vivo breast cancer models, none of the
previous studies have conducted a comparison between
two different pharmacological strategies to inhibit TGF-β
signaling. Thus, our second most important finding is
that both neutralization of active TGF-βs using the 1D11
antibody and inhibition of TGF-β receptor kinases using
the dual receptor kinase inhibitor, LY2109761, resulted in
quantitatively remarkably similar degrees of inhibition of
experimental metastases to both bone and lungs. Besides
inhibiting the TGF-β type I (and -II) receptor kinases,
LY2109761 also inhibits the activin receptor kinases, Alk-
4 and Alk-7. This is a property shared by all known other
members of this class of compounds, raising the concern
that their biological activity may be mediated by either
TGF-βs or activins. On the other hand, 1D11 is specific
for bioactive TGF-βs and does not neutralize any of the
other TGF-β superfamily members, including activin or
BMPs. Thus, the qualitatively and quantitatively similar
anti-metastatic effects we observed using both com-
pounds in both experimental metastasis assays strongly
support a specific role for TGF-β in this process, and
essentially exclude the possibility that the effects we
observed were due to interference with either activin-or
BMP signaling.
In vitro, treatment with exogenous TGF-β induced
Smad2/3 phosphorylation in all six MDA-MB-231 sub-
clones and both TGF-β antagonists were capable of
blocking Smad2/3 signal activation (Figure 2). In addi-
tion, both compounds effectively cause Smad2/3 signal
termination, albeit that LY2109761 induced dephospho-
rylation of Smad2 and -3 more rapidly than 1D11. Con-
sistent with these in vitro findings,  in vivo, phospho-
Smad2 levels were reduced in lungs of animals treated
with either compound compared to vehicle treated con-
trols (Figure 5). Moreover, LY2109761 treatment partly
inhibited mRNA expression of TGF-β target genes, con-
sistent with blockade of endogenous TGF-β signaling in
vivo. These results are consistent with our previous find-
ings using the TGF-β type I receptor inhibitor, SD-208, in
the syngeneic 4T1 mammary cancer model [48]. In con-
trast, 1D11 treatment was not associated with a signifi-
cant reduction in target gene transcript levels by in vivo,
suggesting that this agent only neutralizes activated
ligand and selectively spares endogenous TGF-β signal-
ing.
W e  a n d  o t h e r s  h a v e  r e c e n t l y  r e p o r t e d  t h a t ,  b e s i d e s
Smad2 and -3, TGF-β also activates the BMP Smads,
Smad1 and -5, in normal and malignant mammary and
epidermal epithelial cells [9-11,55,56]. Moreover, the
degree to which exogenous TGF-β induced Smad1/5
phosphorylation in the different subclones appears to
reflect their metastatic ability in vivo (Figure 2). Thus, the
activation state of BMP Smads should be explored as a
predictive biomarker of response to TGF-β antagonists in
a clinical setting.
A major unresolved question is whether and under
which conditions the predominant role TGF-β plays is
mediated by its tumor cell autonomous effects, or via its
actions on the host microenvironment. We approached
this question by comparing two types of bone-tropic
MDA-MB-231 subclones. Following intracardiac inocu-
lation with MDA-MB-231 cells, some animals developed
skeletal metastases following a prolonged period of dor-
mancy (Lu et al., In Preparation). Cell lines derived from
these "post-dormancy" metastases retain clear bone-tro-
pism when re-injected into secondary animals, but dis-
play a gene expression profile that is quite distinct from
that found in the "primary" bone metastases (Lu et al. In
Preparation) [44]. However, when we treated mice that
had been inoculated with post-dormancy bone tropic
2860 TR cells with the 1D11 TGF-β neutralizing anti-
body, the development of skeletal metastases was inhib-
ited to a similar extent as in SCP2-TR inoculated mice
(Figure 4). Thus, 1D11 appeared to be anti-metastatic
independently of the intrinsic gene expression profile of
individual bone tropic tumor cell clones derived from the
same parental cell line. These results suggest that, at least
in this MDA-MB-231 in vivo model, TGF-β's pro-meta-
static activity may be mediated predominantly by its
actions on host cells within the bone microenvironment,
rather than by autocrine effects on the tumor cells them-
selves. Consistent with this idea, neither LY2109761 or
1D11 treatment inhibited tumor cell proliferation or
induced tumor cell apoptosis, in vivo (Figure 6).
I n  r e s p o n s e  t o  a c t i v a t e d  T G F - β  r e l e a s e d  f r o m  b o n e
matrix, MDA-MB-231 cells secrete a number of signaling
molecules, including PTHrP and RANK-L, that stimulate
osteoclast activity [23]. Osteoclast-mediated bone break-
down is thought to release TGF-β, thereby resulting in a
"vicious cycle" that leads to progressive bone destruction
[57]. Thus, we predicted that treatment with TGF-β
antagonists would decrease osteoclast activation in the
context of MDA-MB-231 bone metastases. In fact, 1D11
treatment resulted in a significant reduction in the num-
ber of active osteoclasts at the tumor:bone interface (Fig-
ure 6). Similarly, Futakuchi et al. [57] recently reportedGanapathy et al. Molecular Cancer 2010, 9:122
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that treatment with 1D11 inhibited osteoclast activation
and osteolytic bone destruction by 4T1 mammary carci-
noma cells in vivo. In this study, identical effects were
obtained using a chemical TGF-β type I receptor kinase
inhibitor [57]. Consistent with these findings, Moham-
mad et al. [58] recently reported that treatment with the
TGF-β type I receptor kinase inhibitor, SD-208, increased
osteoblast differentiation and bone formation, while
reducing osteoclast differentiation and bone resorption.
In aggregate, these studies have clearly demonstrated that
pharmacological blockade of TGF-β signaling shifts the
balance from bone breakdown to bone (re)generation,
thereby inhibiting tumor-associated osteolysis.
In t he lung metastasis mode l, trea tmen t wit h T GF-β
pathway antagonists inhibited tumor angiogenesis, as
reflected by a decrease in CD34-positive microvessel
density. These findings are consistent with our own ear-
lier studies of the effects of the TβR-I kinase inhibitor,
SD-208, against 4T1 lung metastases [48]. Similarly, Nam
et al. [54] reported that treatment with 1D11 was associ-
ated with a statistically significant decrease in microves-
sel density in 4T1 murine mammary tumors. Consistent
with these findings, treatment of 4T1 tumor bearing mice
with the 2G7 anti-TGF-β neutralizing antibody signifi-
cantly reduced circulating VEGF levels [59](Genentech,
US Patent Application 2005/0276802 A1). Thus, at least
in lung metastases, TGF-β pathway antagonists have
been consistently found to exert modest anti-angiogenic
effects against basal-like mammary cancer in vivo.
Even though both TGF-β antagonists clearly had a
demonstrable anti-metastatic effect in the MDA-MB-231
human breast cancer models, neither of the two agents
completely abolished skeletal or pulmonary metastases.
In part, this may be due to the fact that we had to use
immunodeficient mice as hosts for human tumor cells
because TGF-β pathway antagonists have been shown to
de-repress anti-tumor immunity in mouse models of
mammary cancer [48,49,52-54]. For example, we our-
selves demonstrated that treatment with the TGF-β type I
receptor kinase inhibitor, SD-208, inhibited spontaneous
pulmonary metastases of R3T mammary carcinoma cells
much more strongly in syngeneic than in nude mice [48].
Published studies have demonstrated that tumor-associ-
ated TGF-β not only suppresses NK cell activity and T-
cell mediated anti-tumor responses, but also actively sub-
verts the CD8+ arm of the immune system into directly
promoting tumor growth by an IL-17-dependent mecha-
nism [48,49,52-54]. As we utilized athymic nude mice as
hosts, we cannot ascribe the observed anti-metastatic
effects of TGF-β antagonists to stimulation of T-cell-
dependent processes. Moreover, even though Arteaga et
al. were able to detect an effect on NK cells, even in the
MDA-MB-231 model [49], we were unable to detect an
increase in NK cell infiltration into metastases of 1D11 or
LY2109761 treated animals in the current study (data not
shown). Thus, we predict that treatment with TGF-β
antagonists will have significantly greater anti-metastatic
impact when applied in the context of a syngeneic host, in
which they will act by a cooperative mechanism that
involves several different cellular compartments, includ-
ing the CD8+ T cells, NK cells, the microvasculature,
osteoclasts and the tumor cells themselves [54].
Finally, we should note that all of the pre-clinical stud-
ies of TGF-β pathway antagonists in mammary cancer
reported to date, have employed cell lines derived from
basal-like tumors. Thus, these studies preclude any con-
clusions regarding the possible anti-metastatic activity
these compounds may or may not have in the context of
estrogen-dependent or HER2-mediated breast cancers.
In fact, a wealth of experimental and clinical evidence
suggests that, as long as breast cancers remain dependent
on estrogens, TGF-β protects against rather than pro-
motes tumor progression [21]. Thus, one has to be cau-
tious in extrapolating the results from the current and
other preclinical studies of TGF-β pathway antagonists to
breast cancers other than those of the basal-like subtype.
Conclusions
In summary, pre-clinical studies in several different syn-
geneic as well as allogeneic mammary cancer models
have provided convincing evidence that targeting the
TGF-β pathway using either a TGF-β neutralizing anti-
body or receptor kinase inhibitors can inhibit both early
lung and bone metastases of basal-like breast cancer. Our
findings are consistent with the concept that TGF-β sig-
naling plays several different roles in the complex inter-
play between tumor and host cells that constitute the pre-
metastatic niche. The signaling pathway appears to be
fundamentally altered in tumor cells in such a way that
the tumor cells interpret incoming signals as pro-inva-
sive, while they are no longer growth inhibited. This
results in the secretion of TGF-β-induced metastasis-
effector proteins, which exert pro-metastatic actions on
the host microenvironment. Our studies provide sub-
stantive support for clinical trials of TGF-β antagonists
for patients with basal-like breast cancer.
Methods
Reagents
Human recombinant TGF-β1 (1 μg/mL; Austral Biologi-
cals, San Ramon, CA) was dissolved in 4 mmol/L HCl
and 1 mg/mL bovine serum albumin (Sigma, St. Louis,
MO). 1D-11 and the isotype-matched murine IgG1
monoclonal control antibody, 13C4, directed against Shi-
gella toxin, (Genzyme, Framingham, MA) was diluted in
formulation buffer composed of 0.1 M glycine, 70 mM
Na2HPO4, 0.0011% Tween 20 for both in vitro and in vivo
studies. A 10 mM stock solution of LY2109761 (Eli LillyGanapathy et al. Molecular Cancer 2010, 9:122
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and Co., Indianapolis, IN) in DMSO (Sigma, St. Louis,
MO) was prepared for in vitro studies. For in vivo studies,
LY2109761 was suspended in a formulation composed of
1% sodium carboxy methylcellulose (NaCMC), 0.5%
sodium lauryl sulfate (SLS), 0.05% antifoam and 0.085%
polyvinylpyrrolidone (PVP).
Cell culture
MDA-231-SCP2TR, MDA-231-SCP25TR, MDA-231-
2860TR and MDA-231-3847TR are clonal sublines of
MDA-MB-231 (ATCC) human breast carcinoma cells
with distinct organ-specific metastatic behavior that were
generated by one of us (YK)[25,42]. MDA-231-4175TR
and MDA-231-4173 were obtained from Dr. Joan Mas-
sagué (Sloan Kettering Institute, New York, NY). All
MDA-MB-231 sublines were maintained in DMEM
(Invitrogen, Carlsbad, CA) supplemented with 10% FBS
(Sigma, St Louis, MO).
Cell proliferation assays
Cells were plated at 2 × 104 cells/well in 24 well cluster
dishes (Corning Inc. Corning, NY), overnight. Cells were
treated initially with 10 μg/ml 1D11 or 2 μM LY2109761
for 15 minutes followed by addition of 100 pM TGF-β1
and incubated at 37°C for 72 h. Subsequently, cells were
washed with 1 ml ice-cold PBS, and detached with 0.2 ml
trypsin-EDTA (Invitrogen, Carlsbad, CA). Trypsin was
neutralized by adding 0.8 ml of the culture medium con-
taining 10% FBS, and the cells counted using a Vi-cell par-
ticle Counter (Beckman Inc, Miami, FL).
Western blot analysis
To determine the effects of TGF-β antagonists on TGF-β-
induced R-Smad phosphorylation, MDA-MB-231 sub-
lines were incubated in serum free medium overnight
and treated with 2 μM LY2109761 or 10 μg/ml 1D11for
15 minutes, followed by the addition of 100 pM TGF-β1
for one hour. The vehicle control, DMSO, was used at a
final concentration of 0.01%, which was not toxic to cells.
For dephosphorylation assays, cells were initially treated
with 100 pM TGF-β for 1.5 hour followed by three
washes with serum free medium. Subsequently, cells were
treated with either 2 μM LY2109761 or 10 μg/ml 1D11 for
0.5, 1, 1.5, 2 and 3 hours. Cells were then lysed in situ
using buffer composed of 150 mM NaCl, 10 mM Tris-
HCl (pH 8.0), 1 mM EGTA, 1% (v/v) Triton-X-100 in the
presence of protease inhibitors and phosphatase inhibi-
tors (Complete Mini Protease Inhibitor Cocktail Tablets
with EDTA, and PhosSTOP, Roche Diagnostics Corpora-
tion, Indianapolis, IN), for 30 min at 4°C. Cell lysates were
collected and clarified by centrifugation at 12,000 rpm for
10 minutes at 4°C. The clarified lysates were then sub-
jected to SDS-PAGE and transferred to nitrocellulose
membranes using a Panther™ Semidry Electroblotter
(Owl Separation Systems, Portsmouth, NH). Activated
Smad2 (pSmad2), Smad3 (pSmad3) and Smad1/5/8
(pSmad1/5/8), were detected using monoclonal rabbit
anti-human pSmad2, polyclonal rabbit anti-human
pSmad3 and polyclonal rabbit anti-human pSmad1/5/8
antibodies (Cell Signaling, Danvers, MA) at 1:1000 dilu-
tions. Total Smad2, Smad3 and Smad1 were detected
using mouse monoclonal anti-human Smad2 (Cell Sig-
naling, Danvers, MA), rabbit monoclonal anti-human
Smad3 (Zymed Laboratories, South San Francisco, CA)
and rabbit monoclonal anti-human Smad1 (Cell Signal-
ing, Danvers, MA) antibodies at 1:400, 1:500, 1:1000 dilu-
tions, respectively. Blots were developed using a 1:2000
dilution of horseradish peroxidase-tagged goat anti-rab-
bit (Calbiochem, San Diego, CA) or anti-mouse (Vector
Labs, Burlingame, CA) IgG antibody and the bands visu-
alized using ECL™ (Amersham, Piscataway, NJ) reagent.
Blots were scanned using a Canoscan Lide500F photo
scanner and integrated optical densities of individual
bands on scanned images were determined using Image J
v.1.41 software (NIH).
In vitro cell motility and invasion assays
Uncoated polyethylene terephthalate (PET) track etched
membrane (24-well insert, pore size 8 μm; BD Biosci-
ences, Franklin Lakes, NJ) inserts were equilibrated by
adding 0.5 ml cell culture medium without FBS to the
upper and lower chambers followed by incubation at
37°C for 2 h. The medium used for equilibration was aspi-
rated gently and upper chambers were seeded with 10 5
cells in 0.5 ml of cell culture medium. TGF-β (100 pM)
and/or 1D11 (10 μg/ml) or LY2109761 (2 μM) were added
to both the upper and lower chambers. Following a 24-
hour incubation at 37°C, cells in suspension were
removed by washing twice with PBS and cells adherent to
the top of the inserts removed by scraping the upper sur-
face of the membrane with cotton tip applicators. The
cells that had migrated to the underside of the inserts
were fixed and stained using the Diff-Quick (Dade Beh-
ring, Newark, DE) staining kit as per manufacturer's
instructions. Cells in ten random squares of 0.1 mm2 in
each well were counted at 200 × magnification, using 3
duplicate wells per assay condition, and expressed as
number of cells per mm2. Invasion assays were carried
out in an identical manner using Matrigel® coated PET
inserts (BD Biosciences, Franklin Lakes, NJ).
Organotypic three-dimensional (3D) cultures
3D cultures were carried out as described by Debnath et
al [60]. Briefly, 5000 cells were plated on top of solidified
Growth Factor Reduced Matrigel®  (BD Biosciences,
Franklin Lakes, NJ) in each well of an 8 well chamber
slide. Cells were fed every other day with cell culture
medium containing 2% (v/v) Matrigel®. Cells were washedGanapathy et al. Molecular Cancer 2010, 9:122
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with PBS on day 9 and fixed with buffered formalin for 10
minutes. For dose-response studies, cells were treated
with vehicle (DMSO 0.28%), or with varying concentra-
tions of LY2109761. All dilutions were made in cell cul-
ture medium supplemented with 10% (v/v) FBS and 2%
(v/v) Matrigel®. Cells were fed every other day with vehi-
cle and LY2109761. On day 9, cells were fixed and perme-
abilized using Triton-X 100 for 5 min, washed with PBS
and incubated in the dark with Alexa Fluor 488 Phalloidin
(1:40 dilution in PBS with 1% BSA, Invitrogen, Carlsbad,
CA). The nuclei were stained using Topro-3 (1:150 dilu-
tion, Invitrogen) for 15 minutes. Stained slides were
mounted with Prolong Antifade Reagent (Invitrogen,
Carlsbad, CA) and photographed using a Zeiss epifluo-
rescence microscope equipped with a MTI CCD camera
and Nikon C1 confocal microscope. Volocity software
(Improvision, Waltham, MA) or Huygens Professional
software (Scientific Volume Imaging, Hilversum, Nether-
lands) renderer modules were used to generate perspec-
tive renderings of each image stack.
Experimental metastasis assays
MDA-231-4175TR tumor cells were injected into the tail
vein (2 × 105 cells) and MDA-231-SCP2TR (1 × 105 cells)
and MDA-231-2860TR (5 × 105 cells) were injected into
the left cardiac ventricle of viral antibody-free 4- to 5-
week-old female athymic nude mice (Harlan Laboratory,
Indianapolis, IN) to give rise to experimental lung and
bone metastases, respectively [42,43]. Starting the follow-
ing day, mice were treated with 5 mg/kg 1D11 anti-TGF-β
antibody, 13C4 control antibody or buffer by intraperito-
neal injection 3 times/week until tumor growth required
sacrifice [61]. Alternatively, mice were treated with 50
mg/kg LY2109761 or 0.2 mL of vehicle by gavage twice a
day, beginning on the second or third day following
tumor cell inoculation, until the animals were sacrificed
[62]. Body weight and bioluminescence were monitored
weekly. For bioluminescence imaging (BLI), anesthetized
mice were injected with 100 mg/kg d-Luciferin (Xenogen,
Alameda, CA) in PBS intraperitoneally, and images were
acquired using a Kodak 2000 MM Multimodal Imaging
Station with cooled CCD camera (Carestream Molecular
Imaging, New Haven, CT). Acquisition time was adjusted
to avoid saturation of the signal. Analysis of the images
was performed using Kodak Molecular Imaging Software
Version 4.5 by first converting the signal to photon flux
(measured in photons/sec/mm2), identifying regions of
interest with a pixel density above background using the
auto ROI feature of the software, and recording the sum
of the background-subtracted pixel values within each
ROI. Results are reported as bioluminescence per treat-
ment group corrected for the number of mice per group.
Post mortem, radiographic images from dissected fore-
limbs and hind limbs of the tumor bearing animals were
taken using X-rays at 35 kVp for 8 seconds using a Fax-
itron LX-60 X-ray cabinet (Faxitron X-Ray, LLC, Lincoln-
shire, IL). The images were then used to quantify lesion
areas using MetaMorph 7.5  image analysis software
(Molecular Devices, Sunnyvale, CA). Lung wet weight at
the time of sacrifice was determined and expressed as a
fraction of body weight. In addition, anterior and poste-
rior photographic images of lungs were obtained from
each animal post mortem and the fraction of lung surface
occupied by metastases determined using NIH Image J
(version 1.41) image analysis software. Besides lungs and
bones, liver, kidneys, adrenal glands, and major lymph
node groups were visually inspected for the presence of
tumor metastases. Organs were fixed in formalin for 24 h
and then placed in 70% ethanol until further histological
assays were performed. In addition, uninvolved kidneys
and lungs were snap frozen in liquid nitrogen for pharma-
codynamic studies using RT-PCR and Western blot anal-
ysis.
Cell proliferation-, apoptosis and angiogenesis
Tissue sections were deparaffinized, rehydrated, and
stained with hematoxylin and eosin (H&E), rat antimouse
monoclonal CD34 IgG2a (1:100; CL8927AP; Cedarlane,
Hornby, Canada), or rabbit polyclonal anti-Ki67 (1:100;
ab833-500; Novus Biologicals, Littleton, CO). Control
slides were stained using appropriate isotope control
antibodies. Biotinylated secondary antibodies (1:150;
Zymed, San Francisco, CA) were used for detection. The
total number of CD34-positive microvessels were
counted in 5 randomly selected high-power (400 ×) fields
in areas of viable tumor. To assess the percentage of pro-
liferating cells, the proportion of Ki-67-positive nuclei
was determined. At least 600 nuclei were counted in 5
randomly selected high-power (400 ×) fields in areas of
viable tumor. Apoptotic cells were identified by terminal
deoxynucleotidyl transferase-mediated nick-end labeling
(TUNEL) assay using the In Situ Cell Death Detection Kit
(Roche Molecular Biochemicals, Indianapolis, IN). To
assess the degree of apoptosis, TUNEL-positive cells
were counted in the tumor in 5 randomly selected high-
power (400 ×) fields in areas of viable tumor.
Histological staining for tartrate resistant acid phosphatase 
(TRAP)
For TRAP staining, bones were fixed in 10% (v/v) forma-
lin followed by decalcification in 0.5 M EDTA. Slides
were incubated with pre-warmed 10% (v/v) naphthol-
ether (0.044 M 7-bromo-3-hydroxy-2-naphthoic-o-ani-
sidide phosphate in ethylene glycol monoethyl ether) in
basic incubation medium (0.112 M sodium acetate, 0.05
M disodium tartrate dihydrate) at 37°C for 30 minutes.
Slides were then transferred directly into 2% (v/v) color
reaction medium (1:1 mixture of 0.058 M NaNO2 andGanapathy et al. Molecular Cancer 2010, 9:122
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0.154 M pararosaniline chloride in 2 M HCl in basic incu-
bation medium), and incubated for 5 to 30 minutes at
room temperature. Once optimal staining was achieved,
slides were rinse in deionized water and counterstained
using Harris's acid hematoxylin. The number of TRAP
positive cells per mm of tumor adjacent to bone were
used as a measure of osteoclast activity [27].
Real-time quantitative RT-PCR
Transcript levels of individual genes were assayed in fro-
zen tissue specimens by quantitative real time (qRT)-
PCR, using the QuantiTect™ Probe RT-PCR Kit (QIA-
GEN, Valencia, CA). For the PCR, 50 μl reactions were
set up with 100 ng of RNA, 0.4 μM primer, 0.2 μM dual
labeled probe, 0.5 μl of QuantiTect™ Reverse Tran-
scriptase Mix and QuantiTect™ Probe RT-PCR Master
Mix. Real time PCR was performed using a Mx4000® Mul-
tiplex Quantitative PCR System (Stratagene, La Jolla, CA)
with each sample assayed in triplicate. Three mRNA spe-
cies were quantified, including CTGF and PAI-1 and the
reference gene, GAPDH. Standard curves for all three
genes were generated using serial dilution of RNA iso-
lated from tissue of control mice. The relative mRNA
amounts for each of the genes in the individual RNA sam-
ples were calculated from the standard curves. The fol-
lowing primers and Taqman probes were used: CTGF:
Forward Primer: 5'-aagggcctcttctgcgattt-3'; Reverse
Primer: 5'-tttggaaggactcaccgctg-3'; Probe: 5'-/56-FAM/
cctgtgtcttcggtgggtcggtgtac/3BHQ_1/-3'.  PAI-1: Forward
Primer: 5'-tgcatcgcctgccattg-3'; Reverse Primer: 5'-ggac-
cttgagataggacagtgctt-3'; Probe: 5'-/56-FAM/tggagggtgc-
catgggcca/3BHQ_1/-3'.  GAPDH: Forward Primer: 5'-
gtcgtggatctgacgtgcc-3'; Reverse Primer: 5'-gatgcctgcttcac-
cacctt-3'; Probe: 5'-/56-FAM/cctggagaaacctgccaagtatgat-
gacat/3BHQ_1/-3'
Statistical analysis
One-way analysis of variance (ANOVA) tests and t-tests
were performed using InStat (GraphPad Software, Inc.,
version 3.1a). Two-way repeated measures ANOVA tests
and survival analyses were carried out using JMP (SAS
Institute Inc., version 8).
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